Skip to main content
Premium Trial:

Request an Annual Quote

Atugen, Byk Gulden Strike Cancer Target Collaboration

NEW YORK, Nov. 19 — German genomics firm atugen has signed an evaluation agreement with countrymate Byk Gulden, the company said on Monday

 

Under the agreement, Byk Gulden, based in Constance, will provide atugen with cancer-associated genetic targets in specific cell lines. Berlin-based atugen will in turn identify biological function of the targets and validate them for potential drug development.

 

Financial details of the agreement were not disclosed.

 

Atugen is focused on high throughput target analysis and validation of pharmaceutical targets. Its GeneBloc technology works by inducing small DNA/RNA hybrid molecules to bind to and destroy target mRNA. This specific mRNA loss can then be correlated with functional changes in vivo and in cell-based assays, leading to an understanding of gene function.

 

Byk Gulden, the pharmaceutical division of ALTANA, specializes in therapeutics for gastrointestinal, respiratory tract, and cardiovascular conditions.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.